{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:03:27Z","timestamp":1758845007950,"version":"3.44.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.urology.2020.11.018","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T15:50:20Z","timestamp":1605887420000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder"],"prefix":"10.1016","volume":"149","author":[{"given":"Li June","family":"Tay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Harry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Malde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2020.11.018_bib0001","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.11.018_bib0002","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/MOU.0b013e32819ed7f9","article-title":"Overactive bladder: an update","volume":"17","author":"Hashim","year":"2007","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urology.2020.11.018_bib0003","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1464-410X.2008.08036.x","article-title":"The economic impact of overactive bladder syndrome in six Western countries","volume":"103","author":"Irwin","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.11.018_bib0004","unstructured":"Recommendations | Urinary incontinence and pelvic organ prolapse in women: management | Guidance | NICE."},{"key":"10.1016\/j.urology.2020.11.018_bib0005","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","article-title":"The NICE cost-effectiveness threshold: what it is and what that means","volume":"26","author":"McCabe","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.urology.2020.11.018_bib0006","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJM197703312961304","article-title":"Foundations of cost-effectiveness analysis for health and medical practices","volume":"296","author":"Weinstein","year":"1977","journal-title":"N Engl J Med"},{"issue":"s1","key":"10.1016\/j.urology.2020.11.018_bib0007","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1111\/j.1524-4733.2009.00515.x","article-title":"QALYs: the basics","volume":"12","author":"Weinstein","year":"2009","journal-title":"Value in Health"},{"key":"10.1016\/j.urology.2020.11.018_bib0008","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modelling for economic evaluation","volume":"13","author":"Briggs","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.urology.2020.11.018_bib0009","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.juro.2009.08.031","article-title":"Cost-Effectiveness of sacral neuromodulation versus intravesical botulinum a toxin for treatment of refractory urge incontinence","volume":"182","author":"Siddiqui","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.11.018_bib0010","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1464-410X.2010.09905.x","article-title":"Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin a treatment for patients with idiopathic overactive bladder","volume":"108","author":"Leong","year":"2011","journal-title":"BJU Int"},{"issue":"7-8 August","key":"10.1016\/j.urology.2020.11.018_bib0011","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5489\/cuaj.2711","article-title":"Economic evaluation of sacral neuromodulation in overactive bladder: a Canadian perspective","volume":"9","author":"Hassouna","year":"2015","journal-title":"J Can Urol Assoc"},{"key":"10.1016\/j.urology.2020.11.018_bib0012","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00345-014-1401-7","article-title":"Sacral neuromodulation and Botulinum toxin a for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System","volume":"33","author":"Bertapelle","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2020.11.018_bib0013","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jval.2010.08.006","article-title":"Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder","volume":"14","author":"Arlandis","year":"2011","journal-title":"Value Heal"},{"key":"10.1016\/j.urology.2020.11.018_bib0014","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.urology.2010.01.080","article-title":"Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder","volume":"76","author":"Watanabe","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.11.018_bib0015","article-title":"Cost-effectiveness of sacral neuromodulation versus OnabotulinumtoxinA for refractory urgency urinary incontinence: results of the ROSETTA Randomized Trial","author":"Harvie","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.11.018_bib0016","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2005.11.006","article-title":"Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre","volume":"49","author":"Kalsi","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.11.018_bib0017","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.juro.2009.01.037","article-title":"Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence","volume":"181","author":"Wu","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.11.018_bib0018","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00192-018-3653-z","article-title":"A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder","volume":"29","author":"Shepherd","year":"2018","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.urology.2020.11.018_bib0019","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/cer-2018-0079","article-title":"Cost\u2013effectiveness of overactive bladder treatments: from the US payer perspective","volume":"8","author":"Murray","year":"2019","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.urology.2020.11.018_bib0020","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/13696998.2016.1199430","article-title":"Economic impact of onabotulinumtoxinA for overactive bladder with urinary incontinence in Europe","volume":"19","author":"Ruff","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.urology.2020.11.018_bib0021","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10198-015-0737-2","article-title":"OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales","volume":"17","author":"Freemantle","year":"2016","journal-title":"Eur J Heal Econ"},{"key":"10.1016\/j.urology.2020.11.018_bib0022","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/SPV.0b013e3182a5deb4","article-title":"Cost-effectiveness of test phase implantation strategies for interstim\u00ae sacral neuromodulation","volume":"19","author":"Kantartzis","year":"2013","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.urology.2020.11.018_bib0023","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.juro.2012.08.085","article-title":"Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation","volume":"189","author":"Martinson","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.11.018_bib0024","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/SPV.0000000000000277","article-title":"Cost-effectiveness analysis of anticholinergics versus botox for urgency urinary incontinence: results from the anticholinergic versus botox comparison randomized trial","volume":"22","author":"Visco","year":"2016","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.urology.2020.11.018_bib0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/nau.23008","article-title":"Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome","volume":"36","author":"Noblett","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2020.11.018_bib0026","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/nau.23908","article-title":"Comparative effectiveness of one versus two-stage sacral neurostimulation device placement","volume":"38","author":"Patel","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2020.11.018_bib0027","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2011.12.011","article-title":"Repeated botulinum toxin type a injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates","volume":"61","author":"Dowson","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.11.018_bib0028","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1464-410X.2012.11282.x","article-title":"Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)","volume":"111","author":"Mohee","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.11.018_bib0029","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","article-title":"A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment","volume":"75","author":"Peyronnet","year":"2019","journal-title":"Eur Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520313947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520313947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:13:22Z","timestamp":1758766402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429520313947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":29,"alternative-id":["S0090429520313947"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2020.11.018","relation":{},"ISSN":["0090-4295"],"issn-type":[{"type":"print","value":"0090-4295"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2020.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}